Close Menu

More articles about Business News

Mission Bay Capital is "expecting to make two to four investments a year over the next three or four years," a QB3 official told GWDN.

The Japanese company will use the technology to offer siRNA reagents to the research community.

The firm expects to report revenues based on an increasing number of system installments.

The investment from new and old investors nearly doubled Metabolon's Series C financing.

The Belgian life sciences company sees the acquisition as bringing together the firm's respective genomics and proteomics capabilities and their European and US presences.

BD plans to place its GeneOhm assays on HandyLab's Jaguar system.

According to Silence, the patent's amended claims "no longer cover other chemical modifications and molecular designs not used by Silence and which therefore do not have an impact on Silence’s core business."

IP Update: Oct 22, 2009


USPTO Publishes Five Patents, Nine Patent Applications Related to RNAi

Affy's revenues rose on product sales and service revenues. Its top and bottom line results missed analysts' estimates, causing its shares to drop sharply.

The firm beat analysts' estimates on the top and bottom line.

The firm sold 5.4 million shares at $7 per share.

Gen-Probe has alleged that BD is infringing several patents that it owns related to molecular diagnostic testing.

Exact Sciences will combine the Invader chemistry with digital PCR technology.

A Roche official said that a "very substantial" portion of the 24 percent growth in qPCR and NAP systems could be attributed to H1N1, with the largest growth in instruments.

The firms are developing a test to differentiate schizophrenia from other psychiatric disorders.

OriGene gains products for DNA and RNA purification and multiplex assays for genotyping, microRNA profiling, and transcription factor activity analysis.

The firm will offer 4.7 million shares at a price of $7 per share.

Illumina and Solexa denied all of Life's and ABI's allegations of patent infringement; asserted that ABI's licensed patents are invalid; and countersued Life and ABI for allegedly infringing four Solexa patents with their SOLiD sequencing system.

According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.

IP Update: Oct 15, 2009


USPTO Publishes One Patent, Eight Patent Applications Related to RNAi


A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.